Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Liu, Shuang ^a,b   Yin, Feng ^a   Fan, Wenhong ^b   Wang, Shuwei ^a   Guo, Xin Ru ^a   Zhang, Jian Ning ^a   Tian, Zeng Min ^a   Fan, Ming ^b,c  

^a NAVY GENERAL HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

1. BMPR IB; 2. Glioblastoma; 3. Growth inhibition; 4. Differentiation

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P21; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BRAIN NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 84861606630     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-52     Document Type: Article

References (29)

1. Malignant glioma: genetics and biology of a grave matter. Maher EA, Furnari FB, Bachoo RM, et al. Genes Dev 2001 15 1311 1333 10.1101/gad.891601 11390353 (Pubitemid 32524640)
2. Combination therapy for malignant glioma based on PTEN status. Gonzalez J, de Groot J, Expert Rev Anticancer Ther 2008 8 1767 1779 10.1586/14737140.8. 11.1767 18983237
3. Therapeutic targeting of EGFR in malignant gliomas. Ye F, Gao Q, Cai MJ, Expert Opin Ther Targets 2010 14 303 316 10.1517/14728221003598948 20148717
4. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor-like cell fraction in glioma xenograft tumors. Folkins C, Man S, Xu P, et al. Cancer Res 2007 67 3560 3564 10.1158/0008-5472.CAN-06- 4238 17440065 (Pubitemid 46762138)
5. Expression and Functional Roles of Smad1/5/8 and BMPR-IB in glioma development. Liu S, Tian Z, Yin F, Fan W, Fan M, Cancer Investig 2009 27 734 740 10.1080/07357900802620786
6. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Hogan BL, Genes Dev 1996 10 1580 1594 10.1101/gad.10.13.1580 8682290 (Pubitemid 26268864)
7. Diversity and pattern in the developing spinal cord. Tanabe Y, Jessell TM, Science 1996 274 1115 1123 10.1126/science.274.5290.1115 8895454 (Pubitemid 26389267)
8. TGF- signaling: receptors, transducers, and Mad proteins. Massagué J, Cell 1996 85 947 950 10.1016/S0092-8674(00)81296-9 8674122 (Pubitemid 26231162)
9. Cytokines and neuronal differentiation. Mehler MF, Kessler JA, Crit Rev Neurobiol 1995 9 419 446 8829854 (Pubitemid 26148320)
10. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Hoodless P, Haerry T, Abdollah S, et al. Cell 1996 85 489 500 10.1016/S0092-8674(00)81250-7 8653785 (Pubitemid 26157188)
11. Smad6 inhibits signalling by the TGF-beta superfamily. Imamura T, Takase M, Nishihara A, et al. Nature 1997 9 622 626 (Pubitemid 27446182)
12. The MAD-related protein Smad7 associates with the TGF- receptor and functions as an antagonist of TGF- signaling. Hayashi H, Abdollah S, Qiu Y, et al. Cell 1997 89 1165 1173 10.1016/S0092-8674(00)80303-7 9215638 (Pubitemid 127678749)
13. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Nakashima K, Yanagisawa M, Arakawa H, et al. Science 1999 284 479 482 10.1126/science.284.5413.479 10205054 (Pubitemid 29289619)
14. Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Ye L, Bokobza SM, Jiang WG, Int J Mol Med 2009 24 591 597 19787192
15. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Lewis-Russell JM, Kyanaston HG, Jiang WG, Histol Histopathol 2007 22 1129 1147 17616940 (Pubitemid 47470307)
16. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Piccirillo SGM, Reynolds BA, Zanetti N, et al. Nature 2006 444 761 765 10.1038/nature05349 17151667 (Pubitemid 44949605)
17. Concise review: Bone morphoge- netic protein pleiotropism in neural stem cells and their derivatives-alternative pathways, convergent signals. Chen HL, Panchision DM, Stem Cells 2007 25 63 68 10.1634/stemcells.2006-0339 16973830 (Pubitemid 46052975)
18. Sequential actions of BMP receptors control neural precursor cell production and fate. Panchision DM, Pickel JM, Studer L, Lee SH, Turner PA, Hazel TG, McKay RD, Genes Dev 2001 15 2094 2110 10.1101/gad.894701 11511541 (Pubitemid 32762053)
19. Emerging roles for bone morphogenetic pro- teins in central nervous system glial biology. Hall AK, Miller RH, J Neurosci Res 2004 76 1 8 10.1002/jnr.20019 15048925 (Pubitemid 38445559)
20. Developmental changes in progenitor cell responsiveness to bone morphoge- netic proteins differentially modulate progressive CNS lineage fate. Mehler MF, Mabie PC, Zhu G, Gokhan S, Kessler JA, Dev Neurosci 2000 22 74 85 10.1159/000017429 10657700 (Pubitemid 30098908)
21. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Lee J, Son MJ, Woolard K, et al. Cancer cell 2008 13 69 80 10.1016/j.ccr.2007.12.005 18167341 (Pubitemid 350309742)
22. p27/kip1 expression in human astrocytic gliomas. Piva R, Cavalla P, Bortolotto S, Cordera S, Richiardi P, Schiffer D, Neurosci Lett 1997 234 127 130 10.1016/S0304-3940(97)00688-5 9364514 (Pubitemid 27452109)
23. p27kip1 contributions to cancer. Nho RS, Sheaff RJ, Prog Cell Cycle Res 2003 5 249 259 14593719
24. Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Alleyne CH, He J, Yang J, et al. Int J Oncol 1999 14 1111 1116 10339666
25. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Kirla RM, Haapasalo HK, Kalimo H, Salminen EK, Cancer 2003 97 644 648 10.1002/cncr.11079 12548606 (Pubitemid 36125841)
26. SKP2 is required for ubiquitin- mediated degradation of the CDK inhibitor p27. Carrano AC, Eytan E, Hershko A, Pagano M, Nat Cell Biol 1999 1 193 199 10.1038/12013 10559916 (Pubitemid 129500937)
27. Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohisto -chemistry and Western blot. Schiffer D, Cavalla P, Fiano V, Ghimenti C, Piva R, Neurosci Lett 2002 328 125 128 10.1016/S0304-3940(02)00483-4 12133571 (Pubitemid 34804727)
28. Modulation of apoptosis by the cyclindependent kinase inhibitor p27 (Kip1). Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ, J Clin Invest 1999 103 597 604 10.1172/JCI5461 10074476 (Pubitemid 29122412)
29. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. Lee SH, McCormick F, J Mol Med 2005 83 296 307 10.1007/s00109-004-0611-7 15605273 (Pubitemid 40674956)